IDXX on Nasdaq
IDEXX Laboratories, Inc.
Logo: http://www.idexx.com/, Public domain, via Wikimedia Commons5
American multinational corporation
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions (as of 2025).3 Its shares trade on Nasdaq under the symbol IDXX.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Quidel, Lantheus Holdings, Inc. or NeoGen, or pick any stock.
- TickerIDXX on Nasdaq1
- Industryhealth care1
- HeadquartersWestbrook1
- Websitewww.idexx.com
- Legal formDelaware corporation1
- Incorporated inDE6
- Business addressOne Idexx Drive, Westbrook, Me 04092-20416
- Filer categoryLarge accelerated filer6
- LEIOGMTXK0LUU1HKV2P0J844
- StatusActive4
- LEI statusIssued and current4
- Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States4
- Registered withDivision of Corporations, Department of State, 20238254
See how the biggest companies compare on our leaderboards
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions (as of 2025).3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 59% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $2.1B | $2.2B | $2.5B |
| Service | $1.6B | $1.6B | $1.8B |
Business segments
Companion Animal Group brought in 92% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Companion Animal Group | $3.4B | $3.6B | $4.0B |
| Water | $168.1M | $185.1M | $201.1M |
| Livestock And Poultry Diagnostics | $121.7M | $122.1M | $131.8M |
Regions
United States brought in 66% of the revenue IDEXX Laboratories, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $2.4B | $2.5B | $2.8B |
| Europe, the Middle East, and Africa, Other | $176.4M | $196.3M | $230.0M |
| Germany | $149.8M | $173.7M | $206.8M |
| Canada | $150.1M | $152.9M | $167.3M |
| United Kingdom | $121.7M | $134.6M | $154.4M |
| France | $96.8M | $110.8M | $126.0M |
| Asia Pacific, Other | $104.1M | $110.1M | $124.4M |
| Australia | $95.5M | $102.0M | $112.2M |
| Latin America and Caribbean | $83.9M | $83.7M | $90.4M |
| Japan | $75.6M | $73.1M | $83.4M |
| Spain | $52.3M | $61.9M | $71.0M |
| Italy | $53.8M | $58.2M | $66.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue38¢$1.6B
- Research and development6¢$251.2M
- Other costs25¢$1.1B
- Income tax6¢$264.7M
- Profit25¢$1.1B
Out of $4.3B in revenue.10
Where each dollar of operating cash went, fiscal 2025
- Capital spending9¢$124.7M
- Share buybacks91¢$1.2B
Out of $1.2B of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.10
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $4.3B | $3.9B | $3.7B |
| Total cost of revenue | $1.6B | $1.5B | $1.5B |
| Gross profit | $2.7B | $2.4B | $2.2B |
| Sales and marketing | $643.5M | $588.5M | $566.1M |
| General and administrative | $404.8M | $442.3M | $335.8M |
| Research and development | $251.2M | $219.8M | $191.0M |
| Total operating expenses | $1.3B | $1.3B | $1.1B |
| Income from operations | $1.4B | $1.1B | $1.1B |
| Interest expense | -$38.9M | -$31.2M | -$41.6M |
| Interest income | $3.0M | $12.7M | $5.6M |
| Income before provision for income taxes | $1.3B | $1.1B | $1.1B |
| Provision for income taxes | $264.7M | $222.0M | $216.1M |
| Net income | $1.1B | $887.9M | $845.0M |
| Basic (in USD per share) | $13.17 | $10.77 | $10.17 |
| Diluted (in USD per share) | $13.08 | $10.67 | $10.06 |
| Basic (in shares) | 80.4M shares | 82.5M shares | 83.1M shares |
| Diluted (in shares) | 81.0M shares | 83.2M shares | 84.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $180.1M | $288.3M | ||
| Accounts receivable, net of allowance of $11,304 in 2025 and $12,585 in 2024 | $552.4M | $473.6M | ||
| Inventories | $377.8M | $381.9M | ||
| Other current assets | $303.6M | $256.2M | ||
| Total current assets | $1.4B | $1.4B | ||
| Property and equipment, net | $747.4M | $713.1M | ||
| Operating lease right-of-use assets | $123.2M | $116.1M | ||
| Goodwill | $414.0M | $405.1M | $366.0M | |
| Intangible assets, net | $109.8M | $111.7M | ||
| Other long-term assets | $542.5M | $547.5M | ||
| Total long-term assets | $1.9B | $1.9B | ||
| TOTAL ASSETS | $3.4B | $3.3B | ||
| Accounts payable | $110.4M | $114.2M | ||
| Accrued liabilities | $530.1M | $502.1M | ||
| Credit Facility | $398.0M | $250.0M | ||
| Current portion of long-term debt | $75.0M | $167.8M | ||
| Current portion of deferred revenue | $35.3M | $33.8M | ||
| Total current liabilities | $1.1B | $1.1B | ||
| Deferred income tax liabilities | $31.9M | $11.3M | ||
| Long-term debt, net of current portion | $374.8M | $449.8M | ||
| Long-term deferred revenue, net of current portion | $32.2M | $26.9M | ||
| Long-term operating lease liabilities, net of current portion | $101.2M | $97.8M | ||
| Other long-term liabilities | $56.5M | $44.3M | ||
| Total long-term liabilities | $596.6M | $630.2M | ||
| Total liabilities | $1.7B | $1.7B | ||
| Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,369 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,712 shares in 2025 and 81,604 shares in 2024 | $10.8M | $10.8M | ||
| Additional paid-in capital | $1.8B | $1.7B | ||
| Deferred stock units: Outstanding: 59 units in 2025 and 60 units in 2024 | $6.1M | $5.9M | ||
| Retained earnings | $6.4B | $5.3B | ||
| Accumulated other comprehensive loss | -$68.8M | -$93.6M | ||
| Treasury stock, at cost: 28,657 shares in 2025 and 26,232 shares in 2024 | -$6.6B | -$5.3B | ||
| Total IDEXX Laboratories, Inc. stockholders equity | $1.6B | $1.6B | $1.5B | $608.7M |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $3.4B | $3.3B | ||
| Accounts receivable, allowance | $11.3M | $12.6M | ||
| Common stock, par value (in USD per share) | $0.10 | $0.10 | $0.10 | $0.10 |
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 108.4M shares | 107.8M shares | ||
| Common stock, shares outstanding (in shares) | 79.7M shares | 81.6M shares | ||
| Deferred stock units, outstanding (in shares) | 59.0K shares | 60.0K shares | ||
| Treasury stock, shares (in shares) | 28.7M shares | 26.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $180.1M | $288.3M | ||
| Accounts receivable, net of allowance of $11,304 in 2025 and $12,585 in 2024 | $552.4M | $473.6M | ||
| Inventories | $377.8M | $381.9M | ||
| Other current assets | $303.6M | $256.2M | ||
| Total current assets | $1.4B | $1.4B | ||
| Property and equipment, net | $747.4M | $713.1M | ||
| Operating lease right-of-use assets | $123.2M | $116.1M | ||
| Goodwill | $414.0M | $405.1M | $366.0M | |
| Intangible assets, net | $109.8M | $111.7M | ||
| Other long-term assets | $542.5M | $547.5M | ||
| Total long-term assets | $1.9B | $1.9B | ||
| TOTAL ASSETS | $3.4B | $3.3B | ||
| Accounts payable | $110.4M | $114.2M | ||
| Accrued liabilities | $530.1M | $502.1M | ||
| Credit Facility | $398.0M | $250.0M | ||
| Current portion of long-term debt | $75.0M | $167.8M | ||
| Current portion of deferred revenue | $35.3M | $33.8M | ||
| Total current liabilities | $1.1B | $1.1B | ||
| Deferred income tax liabilities | $31.9M | $11.3M | ||
| Long-term debt, net of current portion | $374.8M | $449.8M | ||
| Long-term deferred revenue, net of current portion | $32.2M | $26.9M | ||
| Long-term operating lease liabilities, net of current portion | $101.2M | $97.8M | ||
| Other long-term liabilities | $56.5M | $44.3M | ||
| Total long-term liabilities | $596.6M | $630.2M | ||
| Total liabilities | $1.7B | $1.7B | ||
| Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,369 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,712 shares in 2025 and 81,604 shares in 2024 | $10.8M | $10.8M | ||
| Additional paid-in capital | $1.8B | $1.7B | ||
| Deferred stock units: Outstanding: 59 units in 2025 and 60 units in 2024 | $6.1M | $5.9M | ||
| Retained earnings | $6.4B | $5.3B | ||
| Accumulated other comprehensive loss | -$68.8M | -$93.6M | ||
| Treasury stock, at cost: 28,657 shares in 2025 and 26,232 shares in 2024 | -$6.6B | -$5.3B | ||
| Total IDEXX Laboratories, Inc. stockholders equity | $1.6B | $1.6B | $1.5B | $608.7M |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $3.4B | $3.3B | ||
| Accounts receivable, allowance | $11.3M | $12.6M | ||
| Common stock, par value (in USD per share) | $0.10 | $0.10 | $0.10 | $0.10 |
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 108.4M shares | 107.8M shares | ||
| Common stock, shares outstanding (in shares) | 79.7M shares | 81.6M shares | ||
| Deferred stock units, outstanding (in shares) | 59.0K shares | 60.0K shares | ||
| Treasury stock, shares (in shares) | 28.7M shares | 26.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $1.1B | $887.9M | $845.0M |
| Depreciation and amortization | $145.2M | $129.9M | $114.9M |
| Provision for uncollectible accounts | $8.4M | $6.9M | $5.6M |
| Deferred income taxes | $131.2M | -$24.2M | -$48.3M |
| Share-based compensation expense | $60.0M | $60.3M | $59.7M |
| Other | $5.0M | $1.5M | $2.0M |
| Accounts receivable | -$68.7M | -$28.3M | -$53.9M |
| Inventories | -$789.0K | -$28.0M | -$28.7M |
| Accounts payable | -$8.6M | $8.1M | -$557.0K |
| Deferred revenue | $6.9M | -$4.4M | -$3.0M |
| Other assets and liabilities | -$156.4M | -$80.7M | $13.7M |
| Net cash provided by operating activities | $1.2B | $929.0M | $906.5M |
| Purchases of property and equipment | -$124.7M | -$120.9M | -$133.6M |
| Acquisitions of intangible assets | -$13.6M | -$10.0M | $0 |
| Equity investments | -$756.0K | -$1.0M | $0 |
| Acquisitions of businesses, net of cash acquired | $0 | -$76.7M | $0 |
| Proceeds from net investment hedges | $2.7M | $1.6M | $8.4M |
| Net cash used by investing activities | -$136.2M | -$207.1M | -$125.3M |
| Borrowings (payments) on revolving credit facility, net | $148.0M | $0 | -$329.0M |
| Payments of senior notes | -$178.4M | -$75.0M | -$75.0M |
| Borrowings on term loan | $250.0M | $0 | $0 |
| Payments of term loan | -$250.0M | $0 | $0 |
| Debt issuance costs | -$3.7M | $0 | $0 |
| Repurchases of common stock | -$1.2B | -$837.0M | -$71.9M |
| Proceeds from exercises of stock options and employee stock purchase plans | $93.4M | $44.5M | $47.0M |
| Payments of acquisition-related contingent consideration and holdbacks | $0 | $0 | -$3.1M |
| Shares withheld for statutory tax withholding payments on restricted stock | -$7.2M | -$10.5M | -$10.0M |
| Net cash used by financing activities | -$1.2B | -$878.1M | -$442.0M |
| Net effect of changes in exchange rates on cash | $11.2M | -$9.5M | $2.1M |
| Net increase (decrease) in cash and cash equivalents | -$108.2M | -$165.7M | $341.4M |
No quarter-by-quarter statement was filed.
Corporate structure
IDEXX Laboratories, Inc. sits at the top of its group. 44 entities, 27 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of IDEXX Laboratories, Inc.
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on IDEXX Laboratories, Inc., latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on IDEXX Laboratories, Inc., latest Mar 27, 2026 (7 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on IDEXX Laboratories, Inc., latest Apr 17, 2025 (6 filings since Jan 25, 2022)
- Fundsmith LLP Filed SC 13G on IDEXX Laboratories, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2023)
- IDEXX Laboratories, Inc. Wilmington, Delaware, United States
- IDEXX Laboratories (France) Subsidiary
- IDEXX LABORATORIES CANADA CORPORATION Subsidiary · 100% · Toronto, Ontario, Canada
- 342 Saco Street, LLC Subsidiary · Maine, United States
- Beijing IDEXX Laboratories Co. Limited Subsidiary · China
- IDEXX Animana B.V. Subsidiary · Netherlands
- IDEXX B.V. Subsidiary · Hoofddorp, Netherlands
- IDEXX Brasil Laboratórios Ltda. Subsidiary · Brazil
- IDEXX Brasil Participações Ltda. Subsidiary · Brazil
- IDEXX Canada Holdings Corp. Subsidiary · Delaware, United States
- IDEXX Diagnostic Limited Subsidiary · Ireland
- IDEXX Distribution, Inc. Subsidiary · Massachusetts, United States
- IDEXX EUROPE B.V. Subsidiary · Westbrook, Maine, United States
- IDEXX Holding GmbH Subsidiary · Germany
- IDEXX Holdings, Inc. Subsidiary · Delaware, United States
- IDEXX Laboratories (Proprietary) Limited Subsidiary · South Africa
- IDEXX Laboratories (Shanghai) Company Limited Subsidiary · China
- IDEXX Laboratories Canada 1, ULC Subsidiary · Nova Scotia, Canada
- IDEXX Laboratories Danmark ApS Subsidiary · Denmark
- IDEXX Laboratories Hong Kong Limited Subsidiary · Hong Kong
- IDEXX Laboratories II (NZ) ULC Subsidiary · New Zealand
- IDEXX Laboratories Italia S.r.l. Subsidiary · Italy
- IDEXX Laboratories Norge AS Subsidiary · Norway
- IDEXX Laboratories Philippines, Inc. Subsidiary · Philippines
- IDEXX Laboratories Private Limited Subsidiary · India
- IDEXX LABORATORIES PTY LIMITED Subsidiary · Rydalmere, Australia
- and 18 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What IDEXX Laboratories, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $1.7B10 Dec 31, 2025 | $1.5B10 Dec 31, 2024 | +8.1% |
| Accumulated depreciation | $925.7M10 Dec 31, 2025 | $835.0M10 Dec 31, 2024 | +10.9% |
| Property and equipment, net | $747.4M10 Dec 31, 2025 | $713.1M10 Dec 31, 2024 | +4.8% |
| Operating-lease assets (leased space) | $123.2M10 Dec 31, 2025 | $116.1M10 Dec 31, 2024 | +6.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $180.1M10 Dec 31, 2025 | $288.3M10 Dec 31, 2024 | −37.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $414.0M10 Dec 31, 2025 | $405.1M10 Dec 31, 2024 | +2.2% |
| Intangible assets, net (excluding goodwill) | $109.8M10 Dec 31, 2025 | $111.7M10 Dec 31, 2024 | −1.6% |
| Finite-lived intangibles, gross | $190.8M10 Dec 31, 2025 | $172.5M10 Dec 31, 2024 | +10.6% |
| Accumulated amortization | $80.9M10 Dec 31, 2025 | $60.9M10 Dec 31, 2024 | +33.0% |
| Finite-lived intangibles, net | $109.8M10 Dec 31, 2025 | $111.7M10 Dec 31, 2024 | −1.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $377.8M10 Dec 31, 2025 | $381.9M10 Dec 31, 2024 | −1.1% |
| Raw materials | $96.3M10 Dec 31, 2025 | $104.2M10 Dec 31, 2024 | −7.6% |
| Work in process | $32.6M10 Dec 31, 2025 | $31.9M10 Dec 31, 2024 | +2.1% |
| Finished goods | $248.9M10 Dec 31, 2025 | $245.8M10 Dec 31, 2024 | +1.3% |
Properties, in its own words
Our worldwide headquarters and principal executive offices are located in Westbrook, Maine where we engage in manufacturing, research and development, marketing, sales, and general and administrative support functions.
Primary Facility Locations
The rest of Item 2
Location · Functions · Own/Lease
Westbrook, Maine · Worldwide Headquarters, principal executive offices, and CAG manufacturing · Own
Hoofddorp, Netherlands · Distribution center, warehousing, International administrative offices · Lease
Baar, Switzerland · EMEA administrative offices · Lease
Scarborough, Maine · Water, LPD and Supply Chain · Own
Memphis, Tennessee · Distribution center, warehousing, and Reference Lab · Lease
North Grafton, Massachusetts · Reference Lab · Own
West Sacramento, California · Reference Lab · Own
Kornwestheim, Germany · Reference Lab · Own
Wetherby, United Kingdom · Reference Lab · Own
Markham, Ontario, Canada · Reference Lab · Lease
Elmhurst, Illinois · Reference Lab · Lease
Newmarket, United Kingdom · Water manufacturing · Lease
Bern, Switzerland · LPD manufacturing · Lease
Montpellier, France · LPD manufacturing · Lease
Roswell, Georgia · CAG and other manufacturing · Lease
Including the locations above, we have over 50 reference laboratories throughout the United States and over 25 reference laboratories internationally, including locations in Europe, Canada, Australia, New Zealand, Asia, and South Africa. The majority of our reference laboratories are leased, with the remainder being owned. We also lease space in various locations worldwide for administrative support, manufacturing, sales, distribution, and storage. We believe that our leased and owned properties are generally in good condition, are well-maintained, and are generally suitable and adequate to carry on our business.
Item 2 of the 10-K filed Feb 20, 2026.18
Leadership
Who has led IDEXX Laboratories, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerJay Mazelsky Aug 7, 2019 to now19
- Chief executive officerJonathan W. Ayers Feb 15, 2006 to May 6, 201920
- ChairJonathan W. Ayers Feb 16, 2006 to Aug 12, 201921
- PresidentJay Mazelsky Aug 7, 2019 to now19
- PresidentJonathan W. Ayers Feb 15, 2006 to May 6, 201920
- Chief financial officerAndrew Emerson Mar 10, 2025 to now22
- Chief financial officerBrian P. McKeon Jan 3, 2014 to Feb 18, 202523
- Chief financial officerWillard R. Blanche Jr. May 20, 2013 to May 20, 201324
- Chief financial officerMerilee Raines Feb 2, 2006 to Feb 27, 201325
Board members and other officers (49)
- Executive Vice PresidentMichael Schreck Jan 5, 2024 to now26
- Executive Vice PresidentMartin Alexander Smith Aug 30, 2021 to now27
- Executive Vice PresidentNimrata Hunt Jan 24, 2020 to now28
- CVP, Gen. Counsel & SecretarySharon E. Underberg Feb 19, 2020 to now29
- Corporate Vice PresidentMichael Lane May 21, 2018 to now30
- OfficerBrian P. McKeon Feb 17, 2016 to Feb 17, 201631
- CVP, Gen. Counsel & SecretaryJacqueline Studer Sep 3, 2014 to Feb 27, 201932
- EVP, Gen Counsel & SecretaryJeffrey Fiarman May 10, 2013 to Jun 3, 201433
- PRINCIPAL ACCOUNTING OFFICERJeffery D. Chadbourne May 20, 2013 to May 20, 201334
- Executive Vice PresidentJay Mazelsky Aug 16, 2012 to Feb 19, 201935
- CORPORATE VICE PRESIDENTGeorge Fennell Jun 2, 2011 to now36
- CORPORATE VICE PRESIDENTGiovani Twigge Sep 2, 2010 to Feb 25, 202237
- Corporate Vice PresidentDaniel Meyaard V. Dec 30, 2009 to Feb 19, 201338
- Corporate Vice PresidentJames F. Polewaczyk Feb 7, 2007 to Mar 7, 202439
- Corporate Vice PresidentMerilee Raines Feb 16, 2007 to Feb 18, 200940
- Corporate Vice PresidentWilliam B. Goodspeed Aug 1, 2007 to Apr 28, 201141
- Vice PresidentAli Naqui Jan 27, 2006 to May 13, 201342
- Vice PresidentRobert S. Hulsy Feb 3, 2006 to Mar 20, 200743
- Vice President & SecretaryConan R. Deady Feb 16, 2006 to Mar 3, 200644
- Vice PresidentJennifer A. Joiner Feb 16, 2006 to Feb 16, 200645
- Vice PresidentLaurel E. Labauve Feb 16, 2006 to Feb 16, 200646
- Vice PresidentQuentin J. Tonelli Feb 16, 2006 to May 24, 200747
- Vice President and CIOS. Sam Fratoni Feb 16, 2006 to Feb 2, 200948
- Senior Vice President & CSOWilliam C. Wallen Feb 16, 2006 to Feb 17, 201049
- Corporate Vice PresidentThomas J. Dupree Oct 5, 2006 to Feb 22, 201150
- Corporate VP, Worldwide OpsIrene C. Kerr Dec 15, 2006 to Feb 19, 200851
- Board memberJoseph L. Hooley Jul 18, 2025 to now52
- Board memberKaren Peacock Oct 14, 2025 to now53
- Board memberIrene Chang Britt Jul 12, 2023 to now54
- Board memberAsha Collins Nov 20, 2020 to May 8, 202455
- Board memberSamer Abdul Samad Jul 18, 2019 to now56
- Board memberJay Mazelsky Nov 5, 2019 to now57
- Board memberStuart Essig Jul 17, 2017 to now58
- Board memberLawrence D. Kingsley Oct 21, 2016 to now59
- Board memberBruce L. Claflin Jul 24, 2015 to now60
- Board memberDaniel M. Junius Mar 14, 2014 to now61
- Board memberSophie Vandebroek V. Jul 23, 2013 to now62
- Board memberM. Anne Szostak Jul 16, 2012 to now63
- Board memberJoseph Vumbacco V. Mar 4, 2010 to Aug 13, 201264
- Board memberBrian P. McKeon Feb 1, 2006 to May 10, 201365
- Board memberErrol B. Desouza Feb 1, 2006 to May 1, 200966
- Board memberRebecca M. Henderson Feb 1, 2006 to Feb 25, 202167
- Board memberThomas Craig Feb 1, 2006 to May 1, 201768
- Board memberWilliam T. End Feb 1, 2006 to May 11, 201869
- Board memberJonathan W. Ayers Feb 15, 2006 to Sep 9, 202420
- Board memberBarry C. Johnson Mar 17, 2006 to Aug 16, 201670
- Board memberQuentin J. Tonelli Aug 3, 2006 to Aug 3, 200671
- General counselSharon E. Underberg Mar 8, 2019 to Mar 8, 201972
- General counselConan R. Deady Sep 11, 2006 to Mar 7, 201373
Products and brands
Companion Animal Group
The Companion Animal Group (CAG) provides in-clinic laboratory analyzers for companion animals. Analyzers measure blood cell counts as well as levels of certain enzymes in blood or urine for the purpose of monitoring health conditions. Major products of this segment are the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, Symmetric dimethylarginine (SDMA), ProCyte Dx Hematology Analyzer, the LaserCyte Hematology Analyzer, the IDEXX VetAutoread Hematology Analyzer, the SNAP Pro analyzer, and so on, among other laboratory equipment and analytical services.
Water testing
The Water segment provides products to measure microbiological parameters in water. Popular products of this segment include Colilert, Colilert-18, and Colisure for detecting total coliform and E. coli. Water products are sold in over 120 countries around the globe.
Livestock and Poultry Diagnostics
The Livestock and Poultry Diagnostics division provides products to detect diseases in livestock and poultry. Products of this segment include tests for avian influenza, bovine viral diarrhoea virus, porcine reproductive and respiratory syndrome (PRRS), and bovine spongiform encephalopathy (BSE or mad cow disease).
From Wikipedia’s article on Idexx Laboratories, shared under CC BY-SA 4.0.7
Subsidiaries and ownership
Subsidiaries
Subsidiaries (Exhibit 21)
- 342 Saco Street, LLC Maine8
- Beijing IDEXX Laboratories Co. Limited China8
- IDEXX Animana B.V. Netherlands8
- IDEXX B.V. Netherlands8
- IDEXX Brasil Laboratórios Ltda. Brazil8
- IDEXX Brasil Participações Ltda. Brazil8
- IDEXX Canada Holdings Corp. Delaware8
- IDEXX Diagnostic Limited Ireland8
- IDEXX Distribution, Inc. Massachusetts8
- IDEXX GmbH Germany8
- IDEXX Holding GmbH Germany8
- IDEXX Holdings, Inc. Delaware8
- IDEXX Laboratories (Proprietary) Limited South Africa8
- IDEXX Laboratories (Shanghai) Company Limited China8
- IDEXX Laboratories B.V. Netherlands8
- IDEXX Laboratories Canada 1, ULC Nova Scotia8
- IDEXX Laboratories Canada Corporation Nova Scotia8
- IDEXX Laboratories Co., Ltd. Thailand8
- IDEXX Laboratories Danmark ApS Denmark8
- IDEXX Laboratories Hong Kong Limited Hong Kong8
- IDEXX Laboratories II (NZ) ULC New Zealand8
- IDEXX Laboratories Italia S.r.l. Italy8
- IDEXX Laboratories Limited England & Wales8
- IDEXX Laboratories Ltd. Korea, Republic of8
All 49 listed subsidiaries
- IDEXX Laboratories Norge AS Norway8
- IDEXX Laboratories Oy Finland8
- IDEXX Laboratories Philippines, Inc. Philippines8
- IDEXX Laboratories Private Limited India8
- IDEXX Laboratories SRL Belgium8
- IDEXX Laboratories Singapore Pte. Ltd. Singapore8
- IDEXX Laboratories Sp. z o.o. Poland8
- IDEXX Laboratories Sverige AB Sweden8
- IDEXX Laboratories s.r.o. Czech Republic8
- IDEXX Laboratories, KK Japan8
- IDEXX Laboratories, S.de R.L. de C.V. Mexico8
- IDEXX Laboratorios, S.L. Spain8
- IDEXX Montpellier SAS France8
- IDEXX Operations, Inc. Delaware8
- IDEXX Pharmaceuticals, LLC Delaware8
- IDEXX Real Estate Holdings GmbH Germany8
- IDEXX Real Estate Holdings, LLC Maine8
- IDEXX SARL France8
- IDEXX Technologies Limited England & Wales8
- IDEXX UK Acquisition Limited England & Wales8
- IDEXX Vet Med Labor GmbH Austria8
- IDEXXLAB, Unipessoal Lda. Portugal8
- Laboratoire IDEXX SARL France8
- OPTI Medical Systems, Inc. Delaware8
- Vet Med Labor GmbH Germany8
From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 4, 20268-K Results of operations74
- May 15, 20268-K Bylaws or fiscal year changed; Shareholder vote75
- May 5, 20268-K Results of operations76
- Mar 26, 20268-K Executive or director change77
- Feb 13, 20268-K Executive or director change78
- Feb 2, 20268-K Results of operations79
- Jan 13, 20268-K Executive or director change; Regulation FD disclosure80
- Nov 13, 20258-K Entered a material agreement; New debt or obligation81
- Nov 3, 20258-K Results of operations82
- Oct 7, 20258-K Executive or director change83
- Aug 4, 20258-K Results of operations84
- Jul 10, 20258-K Executive or director change85
- Aug 7, 2019New chief executive Jay Mazelsky becomes CEO19
- Feb 15, 2006New chief executive Jonathan W. Ayers becomes CEO20
- 1983Founded Founded1
Calendar
Coming up
- Nov 2, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $3.40 a share, on Nov 3, 2025.86
When it reported results
- Aug 4, 2026Reported quarterly or annual results74
- May 5, 2026Reported quarterly or annual results76
- Feb 2, 2026Reported quarterly or annual results79
- Nov 3, 2025Reported quarterly or annual results82
- Aug 4, 2025Reported quarterly or annual results84
- May 1, 2025Reported quarterly or annual results87
- Feb 3, 2025Reported quarterly or annual results88
- Oct 31, 2024Reported quarterly or annual results89
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
405 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 257 insider forms, 16 large holders, 68 other. The latest 20:
- Sep 9, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Aug 24, 20264 EDGAR
- Aug 4, 20268-K EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 3, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 1, 2026SD EDGAR
- May 20, 2026144 EDGAR
- May 15, 20268-K EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 11, 20264 EDGAR
The 405 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
57 open-market trades by officers, directors and large owners since October 2021: 0 buys and 57 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Kingsley Lawrence DDirector | Sale | 2,203 | $532.08 | $1.2M | Form 4 |
| Mar 3, 2026 | Hunt NimrataExecutive Vice President | Sale | 1,758 | $634.57 | $1.1M | Form 4 |
| Feb 26, 2026 | MAZELSKY JONATHAN JAYPresident and CEO | Sale | 23,326 | $657.55 | $15.3M | Form 4 |
| Feb 26, 2026 | Hunt NimrataExecutive Vice President | Sale | 2,693 | $661.54 | $1.8M | Form 4 |
| Feb 17, 2026 | Erickson Michael GExecutive Vice President | Sale | 5,371 | $627.38 | $3.4M | Form 4 |
| Feb 17, 2026 | Vandebroek Sophie V.Director | Sale | 1,464 | $628.62 | $920.3K | Form 4 |
| Feb 10, 2026 | FENNELL GEORGEExecutive Vice President | Sale | 11,345 | $646.72 | $7.3M | Form 4 |
| Nov 7, 2025 | Hunt NimrataExecutive Vice President | Sale | 9,425 | $703.34 | $6.6M | Form 4 |
| Aug 22, 2025 | SZOSTAK M ANNEDirector | Sale | 2,187 | $647.33 | $1.4M | Form 4 |
| Aug 12, 2025 | Erickson Michael GExecutive Vice President | Sale | 406 | $649.96 | $263.8K | Form 4 |
| Aug 11, 2025 | Hunt NimrataExecutive Vice President | Sale | 1,200 | $656.53 | $787.8K | Form 4 |
| Aug 8, 2025 | Underberg Sharon E.EVP, GC & Corporate Secretary | Sale | 5,450 | $651.60 | $3.6M | Form 4 |
| Aug 6, 2025 | Hunt NimrataExecutive Vice President | Sale | 7,143 | $630.43 | $4.5M | Form 4 |
| Aug 6, 2025 | MAZELSKY JONATHAN JAYPresident and CEO | Sale | 29,260 | $631.98 | $18.5M | Form 4 |
| Aug 6, 2025 | Lane MichaelExecutive Vice President | Sale | 8,411 | $627.73 | $5.3M | Form 4 |
| May 21, 2025 | SZOSTAK M ANNEDirector | Sale | 2,306 | $512.98 | $1.2M | Form 4 |
| May 13, 2025 | JUNIUS DANIEL MDirector | Sale | 2,683 | $506.41 | $1.4M | Form 4 |
| May 9, 2025 | Vandebroek Sophie V.Director | Sale | 1,279 | $491.34 | $628.4K | Form 4 |
| Feb 10, 2025 | FENNELL GEORGEExecutive Vice President | Sale | 9,986 | $462.53 | $4.6M | Form 4 |
| Feb 7, 2025 | SZOSTAK M ANNEDirector | Sale | 3,000 | $465.95 | $1.4M | Form 4 |
All 57 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202690
- VANGUARD GROUP INCSCHEDULE 13G/A, 7 filings Feb 10, 2022 to Mar 27, 202691
- BlackRockSCHEDULE 13G/A, 6 filings Jan 25, 2022 to Apr 17, 202592
- Fundsmith LLPSC 13G, 2 filings Feb 14, 202393
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Jonathan J. MazelskyPresident and Chief Executive Officer | $1.1M | $14.6M94 | |
| 2025 | Michael J. LaneExecutive Vice President and General Manager, CAG Diagnostics Business Unit | 58 | $594.1K | $4.0M94 |
| 2025 | Tina Hunt, PhDExecutive Vice President, Global Strategy and Commercial | 58 | $594.1K | $3.9M94 |
| 2025 | Martin Smith, PhDExecutive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | 58 | $594.1K | $3.9M94 |
| 2025 | Andrew EmersonExecutive Vice President and Chief Financial Officer | 43 | $531.1K | $3.0M94 |
| 2025 | Brian P. McKeonFormer Executive Vice President, Chief Financial Officer and Treasurer | $293.4K | $351.7K94 | |
| 2024 | Jonathan J. MazelskyPresident and Chief Executive Officer | $1.1M | $13.0M94 | |
| 2024 | Brian P. McKeonFormer Executive Vice President, Chief Financial Officer and Treasurer | $689.6K | $3.9M94 | |
| 2024 | Tina Hunt, PhDExecutive Vice President, Global Strategy and Commercial | 58 | $576.6K | $3.7M94 |
| 2024 | Michael J. LaneExecutive Vice President and General Manager, CAG Diagnostics Business Unit | 58 | $576.6K | $3.7M94 |
| 2024 | Martin Smith, PhDExecutive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | 58 | $576.6K | $3.7M94 |
| 2023 | Jonathan J. MazelskyPresident and Chief Executive Officer | $1.0M | $11.5M94 | |
| 2023 | Brian P. McKeonFormer Executive Vice President, Chief Financial Officer and Treasurer | $669.0K | $3.8M94 | |
| 2023 | Tina Hunt, PhDExecutive Vice President, Global Strategy and Commercial | 58 | $559.2K | $3.6M94 |
| 2023 | Michael J. LaneExecutive Vice President and General Manager, CAG Diagnostics Business Unit | 58 | $559.2K | $2.9M94 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 8,170,178 | $4.3B | 0.1% | −195,375 |
| Vanguard Capital Management LLC | 5,152,213 | $2.7B | 0.1% | −30,294 |
| Vanguard Portfolio Management LLC | 3,896,521 | $2.1B | 0.1% | −14,342 |
| State Street Corp | 3,748,660 | $2.0B | 0.1% | +74,475 |
| Invesco Ltd. | 3,611,416 | $1.9B | 0.2% | +261,739 |
| Geode Capital Management, LLC | 2,562,886 | $1.3B | 0.1% | −98,113 |
| Bamco Inc /ny/ | 1,976,778 | $1.0B | 1.6% | +343,411 |
| Morgan Stanley | 1,356,103 | $713.9M | 0.0% | +40,149 |
| Bank of New York Mellon Corp | 1,193,343 | $628.2M | 0.1% | −311,189 |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | $561.8M | 0.2% | +228,239 |
| Fundsmith LLP | 1,019,887 | $536.9M | 3.9% | −445,899 |
| Blair William & Co/il | 918,556 | $483.6M | 1.3% | −27,780 |
| Northern Trust Corp | 918,137 | $483.3M | 0.1% | +6,244 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 911,489 | $479.8M | 0.1% | +39,700 |
| Fmr LLC | 822,643 | $433.1M | 0.0% | +539,667 |
| American Century Companies Inc | 808,358 | $425.6M | 0.2% | +208,427 |
| Capital Research Global Investors | 789,111 | $415.5M | 0.1% | +7,766 |
| Jpmorgan Chase & Co | 755,791 | $405.1M | 0.0% | −24,091 |
| Principal Financial Group Inc | 743,246 | $391.3M | 0.2% | −137,943 |
| Goldman Sachs Group Inc | 738,708 | $388.9M | 0.0% | +21,787 |
| Wellington Management Group Llp | 726,695 | $382.6M | 0.1% | −8,780 |
| Charles Schwab Investment Management Inc | 650,429 | $342.4M | 0.0% | +40,212 |
| Legal & General Group Plc | 617,197 | $324.9M | 0.1% | −33,606 |
| Dimensional Fund Advisors LP | 608,902 | $320.6M | 0.1% | +35,570 |
| Franklin Resources Inc | 575,784 | $303.1M | 0.1% | −86,849 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
21 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jan 13, 2026 | April McClain DelaneyDemocratic, House | Sale | $1,001 - $15,000 | +34.6% | Report |
| Oct 16, 2025 | April McClain DelaneyDemocratic, House | Partial sale | $1,001 - $15,000 | +31.0% | Report |
| Sep 4, 2025 | Byron DonaldsRepublican, House | Buy | $1,001 - $15,000 | −33.5% | Report |
| Sep 4, 2025 | Byron DonaldsRepublican, House | Buy | $1,001 - $15,000 | −33.5% | Report |
| Aug 7, 2025 | April McClain DelaneyDemocratic, House | Partial sale | $1,001 - $15,000 | +37.9% | Report |
| Jul 9, 2025 | April McClain DelaneyDemocratic, House | Partial sale | $1,001 - $15,000 | +22.5% | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr.Republican, House | Buy | $1,001 - $15,000 | −23.8% | Report |
| May 12, 2025 | Jefferson ShreveRepublican, House | Sale | $100,001 - $250,000 | +25.0% | Report |
| Apr 9, 2025 | April McClain DelaneyDemocratic, House | Buy | $1,001 - $15,000 | −2.9% | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr.Republican, House | Sale | $1,001 - $15,000 | +3.9% | Report |
| Apr 7, 2025 | April McClain DelaneyDemocratic, House | Buy | $1,001 - $15,000 | −8.6% | Report |
| Apr 7, 2025 | Jefferson ShreveRepublican, House | Buy | $50,001 - $100,000 | −8.6% | Report |
| Apr 4, 2025 | April McClain DelaneyDemocratic, House | Buy | $1,001 - $15,000 | −13.8% | Report |
| Apr 1, 2025 | April McClain DelaneyDemocratic, House | Buy | $1,001 - $15,000 | −6.9% | Report |
| Mar 14, 2025 | April McClain DelaneyDemocratic, House | Buy | $1,001 - $15,000 | −5.4% | Report |
| Mar 13, 2025 | Jefferson ShreveRepublican, House | Buy | $15,001 - $50,000 | −5.3% | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr.Republican, House | Buy | $1,001 - $15,000 | −10.9% | Report |
| Jan 22, 2024 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +56.7% | Report |
| Apr 3, 2023 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −76.0% | Report |
| Oct 5, 2022 | Tommy TubervilleRepublican, Senate | Sale | $1,001 - $15,000 | +48.4% | Report |
| Mar 29, 2021 | Tommy TubervilleRepublican, Senate | Buy | $1,001 - $15,000 | −80.8% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How IDEXX Laboratories, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARIDEXX LABORATORIES INC /DE2
- CIK0000874716
- Employer ID (EIN)01-039372318
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company18
- Incorporated inDelaware18
- Fiscal year endsDecember 312
- Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business addressOne Idexx Drive, Westbrook, ME 04092-20412
- Phone20755603002
- Shares outstanding78,781,116 as of Jul 31, 202616
- Public float$42.9B as of Jun 30, 202518
- AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts PCAOB ID 238; it also attests to the company’s internal control over financial reporting18
- On EDGAR sinceFeb 7, 19962
- Filings2,156 in all: 4 (1,384), 8-K (196), SC 13G/A (130), 10-Q (91), 3 (48), 144 (42), DEF 14A (30), SC 13G (28)2
All 34 form types
10-K (27), DEFA14A (19), ARS (18), S-8 (17), UPLOAD (17), 4/A (16), CT ORDER (15), CORRESP (14), SD (13), 8-K/A (9), S-8 POS (9), 5 (6), 3/A (4), 10-K405 (3), 8-A12G/A (3), PRE 14A (3), 10-Q/A (2), DEFR14A (2), S-3 (2), SCHEDULE 13G/A (2), 10-K405/A (1), 5/A (1), 8-A12G (1), PRER14A (1), S-3/A (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Feb 20, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Mar 27, 2026
Latest 8-K (8-K) Aug 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.10 par value per share | IDXX | NASDAQ Global Select Market |
From the cover page of the 10-K filed Feb 20, 2026 (Section 12(b) of the Exchange Act).18
Risk factors and legal proceedings
The risks IDEXX Laboratories, Inc. names in Item 1A of its 10-K filed Feb 20, 2026: 24 risks under these headings, as written.18
- RISKS RELATED TO OUR BUSINESS AND INDUSTRY
- Our business lines are highly attractive and highly competitive. Our failure to successfully execute certain strategies in this competitive environment could have a material negative impact on our future growth and profitability
- Our dependence on third-party suppliers could negatively affect our ability to sell certain products or deliver our cloud-based software solutions, which could negatively affect our operating results
- Our biologic products are complex and difficult to manufacture, which could negatively affect our ability to supply our customers
- Issues in our use of AI may result in reputational harm or liability and adversely affect our business
- Various U.S. and foreign government regulations could limit or delay our ability to market and sell our products or otherwise negatively impact our business
- Our success is heavily dependent on our continued differentiated product and service innovation
- Increased competition from and technological advances by our competitors could negatively affect our operating results
- Consolidation in our customer base, including through increased corporate hospital ownership, and prevalence of buying consortiums could negatively affect our business
- Changes in testing patterns could negatively affect our operating results
- We sell many products through distributors, which presents risks that could negatively affect our operating results
- GENERAL RISKS
The other 14 risks
- We depend on the efforts of key personnel and talent to succeed and compete effectively
- We depend on the continuous and reliable operation and security of our information technology systems and our products and services that incorporate or rely on information technology, and any disruption or significant cybersecurity breach or other incident could adversely affect our business
- Factors and events beyond our control could disrupt our operations, supply chain, and logistics network and adversely affect our business
- Since our business is global in nature, geopolitical risks and other risks associated with doing business internationally could negatively affect our business, financial condition, and operating results
- A weak worldwide economy, or actual or perceived economic weakness in any significant geography, could result in reduced demand for our products and services or increased customer credit risk
- We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our financial condition and results of operations
- Our operations and reputation may be impaired if we, our products, or our services do not comply with our global privacy policy or evolving laws, regulations, and industry standards regarding data privacy and protection
- Failure to meet current or evolving environmental, social, and governance regulations, standards, or expectations or to achieve our environmental, social, or governance goals could adversely affect our business, results of operations, financial condition, reputation, or stock price
- Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business, financial condition, and results of operation
- Future operating results could be negatively affected by changes in tax rates, the adoption of new tax legislation or exposure to additional tax liabilities
- Strengthening of the rate of exchange for the U.S. dollar has a negative effect on our business
- Restrictions in our debt agreements or our inability to obtain financing on favorable terms may increase our cost of borrowing and limit our activities
- RISKS RELATED TO AN INVESTMENT IN OUR SECURITIES
- Fluctuations in our quarterly or annual results may cause our stock price to decline
- The market price of our common stock may be volatile, and you may not be able to resell your shares at or above the price you paid
Legal proceedings
Due to the nature of our activities, we are at times subject to pending and threatened legal actions that arise out of the ordinary course of business. In the opinion of management, based in part upon advice of legal counsel, the disposition of any such currently pending or threatened matters is not expected to have a material effect on our results of operations, financial condition, or cash flows. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that our results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.
The opening of Item 3, Legal Proceedings.18
Links
- Websitewww.idexx.com1
- Facebookwww.facebook.com/IDEXX1
- YouTubewww.youtube.com/channel/UCJuQRh7JkUW5AI34eG0y3Pg1
- WikipediaIdexx Laboratories
- More imagesWikimedia Commons
- WikidataQ1758392
- SEC EDGARCIK 874716
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARJonathan W. Ayers, Chair
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARBrian P. McKeon, Officer
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42SEC EDGARAli Naqui, Vice President
- 43SEC EDGARRobert S. Hulsy, Vice President
- 44
- 45SEC EDGARJennifer A. Joiner, Vice President
- 46SEC EDGARLaurel E. Labauve, Vice President
- 47SEC EDGARQuentin J. Tonelli, Vice President
- 48
- 49
- 50
- 51
- 52SEC EDGARJoseph L. Hooley, Board member
- 53SEC EDGARKaren Peacock, Board member
- 54SEC EDGARIrene Chang Britt, Board member
- 55SEC EDGARAsha Collins, Board member
- 56SEC EDGARSamer Abdul Samad, Board member
- 57SEC EDGARJay Mazelsky, Board member
- 58SEC EDGARStuart Essig, Board member
- 59SEC EDGARLawrence D. Kingsley, Board member
- 60SEC EDGARBruce L. Claflin, Board member
- 61SEC EDGARDaniel M. Junius, Board member
- 62SEC EDGARSophie Vandebroek V., Board member
- 63SEC EDGARM. Anne Szostak, Board member
- 64SEC EDGARJoseph Vumbacco V., Board member
- 65SEC EDGARBrian P. McKeon, Board member
- 66SEC EDGARErrol B. Desouza, Board member
- 67SEC EDGARRebecca M. Henderson, Board member
- 68SEC EDGARThomas Craig, Board member
- 69SEC EDGARWilliam T. End, Board member
- 70SEC EDGARBarry C. Johnson, Board member
- 71SEC EDGARQuentin J. Tonelli, Board member
- 72SEC EDGARSharon E. Underberg, General counsel
- 73SEC EDGARConan R. Deady, General counsel
- 74SEC EDGARResults of operations
- 75
- 76SEC EDGARResults of operations
- 77SEC EDGARExecutive or director change
- 78SEC EDGARExecutive or director change
- 79SEC EDGARResults of operations
- 80
- 81
- 82SEC EDGARResults of operations
- 83SEC EDGARExecutive or director change
- 84SEC EDGARResults of operations
- 85SEC EDGARExecutive or director change
- 86NasdaqNasdaq calendar
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94